Blockchain Registration Transaction Record

Quantum BioPharma Appoints Kevin Malone as Advisor, Focused on Shareholder Protection and Therapeutic Solutions

Quantum BioPharma appoints Kevin Malone as advisor, emphasizing shareholder protection values and therapeutic focus. Malone brings expertise in wealth management and market pattern recognition, aligning with the company's mission against trading manipulation. Company focuses on innovative solutions for neurodegenerative disorders, such as Lucid-MS, a compound targeting multiple sclerosis.

This news highlights the collaboration between Quantum BioPharma and Kevin Malone, emphasizing the company's commitment to combating trading manipulation and developing treatments for challenging disorders. The appointment signifies a strategic move towards enhancing shareholder protection values and advancing therapeutic research, potentially impacting the future of neurodegenerative disorder treatments.